Evaluation of possible pro- or antioxidative properties and of the interaction capacity with the microsomal cytochrome P450 system of different NMDA-receptor ligands and of taurine in vitro

Experimental and Toxicologic Pathology

Volumn 54, Issue 5-6, 2003, Pages 441-448

  Lupp, Amelie ^a   Kerst, Steffen ^a   Karge, Elke ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Amantadine; AP 5; Budipine; Cytochrome P450; Dizocilpine; Free radicals; Ketamine; Memantine; NMDA; Taurine

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 7 ETHOXYCOUMARIN DEETHYLASE; AMANTADINE; ANTIOXIDANT; BUDIPINE; CYTOCHROME P450; DIZOCILPINE; ETHOXYRESORUFIN DEETHYLASE; ETHYLMORPHINE N DEMETHYLASE; GLUTAMIC ACID; HYDROGEN PEROXIDE; KETAMINE; LIPID; LUCIGENIN; LUMINOL; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXIDOREDUCTASE; TAURINE; UNSPECIFIC MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BIOTRANSFORMATION; BLOOD ANALYSIS; BRAIN MICROSOME; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMETHYLATION; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVITY; IN VITRO STUDY; LIPID PEROXIDATION; LIVER MICROSOME; MALE; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; RAT; SUPERNATANT;

ANIMALIA;

EID: 0037559371     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1078/0940-2993-00280     Document Type: Article

References (49)

1. ANITHA-NANDHINI AT, BALAKRISHNAN SD, ANURADHA CV: Taurine modulates antioxidant potential and controls lipid peroxidation in the aorta of high fructose-fed rats. J Biochem Mol Biol Biophys 2002; 6: 129-133.
2. ADAMS JD Jr, CHANG ML, KLAIDMAN L: Parkinson's disease - redox mechanisms. Curr Med Chem 2001; 8: 809-814.
3. AITIO A: A simple and sensitive assay of 7-ethoxycoumarin deethylation. Anal Biochem 1978; 85: 488-491.
4. ALLEN RC: Phagocytic leukocyte oxygenation activities and chemiluminescence: a kinetic approach to analysis. Methods Enzymol 1986; 133: 449-491.
5. ARUOMA OI, HALLIWELL B, HOEY BM, et al.: The antioxidant action of taurine, hypotaurine and their metabolic precursors. Biochem J 1988; 256: 251-255.
6. BALKAN J, KANBAOU O, HATIPOGLU A, et al.: Improving effect of dietary taurine supplementation on the oxidative stress and lipid levels in the plasma, liver and aorta of rabbits fed on a high-cholesterol diet. Biosci Biotechnol Biochem 2002a; 66: 1755-1758.
7. BALKAN J, KANBAGLI O, AYKAC-TOKER G, et al.: Taurine treatment reduces hepatic lipids and oxidative stress in chronically ethanol-treated rats. Biol Pharm Bull 2002b; 25: 1231-1233.
8. BELANGER PM, GRECH-BELANGER O, LABADIE R: Depression of hepatic microsomal enzyme systems by amantadine hydrochloride in the rat. J Pharmacol Exp Ther 1979; 211: 285-490.
9. BETHKE TH, MERZ M, ZECH K, et al.: Dose linearity and steady state pharmacokinetics of the new antiparkinson agent budipine after oral administration. Int J Clin Pharmacol Ther 2001; 39: 259-264.
10. BUEGE JKA, AUST SD: Microsomal lipid peroxidation. Methods Enzymol 1978; 52: 302-310.
11. CORREIA MA: Rat and human liver cytochrome P450: substrate and inhibitor specificities and functional markers. In: ORTIZ DE MONTELLANO PR (Ed.): Cytochrome P450: structure, mechanism and biochemistry. Plenum Press, New York, London 1995: 607-630.
12. COZZI R, RICORDY R, BARTOLINI F, et al.: Taurine and ellagic acid: two differently-acting natural antioxidants. Environ Mol Mutagen 1995; 26: 248-254.
13. CUZZOCREA S, RILEY DP, CAPUTI AP, et al.: Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 2001; 53: 135-159.
14. DEVAMANOHARAN PS, ALI AH, VARMA SD: Oxidative stress to rat lens in vitro: protection by taurine. Free Radic Res 1998; 29: 189-195.
15. DOGRU-ABBASOGLU S, KANBAGLI O, BALKAN J, et al.: The protective effect of taurine against thioacetamide hepatotoxicity of rats. Hum Exp Toxicol 2001; 20: 23-27.
16. FACCHINETTI F, DAWSON VL, DAWSON TM: Free radicals as mediators of neuronal injury. Cell Mol Neurobiol 1998; 18: 667-682.
17. FREUDENTHALER S, MEINEKE I, SCHREEB KH, et al.: Influence of urine pH and urinary flow on the renal excretion of memantine. Br J Clin Pharmacol 1998; 46: 541-546.
18. GIASSON BI, ISCHIROPOULOS H, LEE VM, et al.: The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radic Biol Med 2002; 32: 1264-1275.
19. GURER H, OZGUNES H, SAYGIN E, et al.: Antioxidant effect of taurine against lead-induced oxidative stress. Arch Environ Contam Toxicol 2001; 41: 397-402.
20. HILDEBRANDT AG, ROOTS I, TJOE M: Hydrogen peroxide in hepatic microsomes. Methods Enzymol 1978; 52: 342-350.
21. HOGG N: Free radicals in disease. Semin Reprod Endocrinol. 1998; 16: 241-248.
22. IDVALL J, AHLGREN I, ARONSEN KR, et al.: Ketamine infusions: pharmacokinetics and clinical effects. Br J Anaesthesia 1979; 51: 1167-1173.
23. IGNATOWICZ E, RYBCZYNSKA M: Some biochemical and pharmacological aspects of free radical-mediated tissue damage. Pol J Pharmacol 1994; 46: 103-114.
24. JENNER P: Oxidative stress in Parkinson's disease and other neurodegenerative disorders. Pathol Biol (Paris) 1996; 44: 57-64.
25. KEHRER JP: Free radicals as mediators of tissue injury and disease. Crit Rev Toxicol 1993; 23: 21-48.
26. KHLOPUSHINA TG, KRINSKAIA AV: The effect of the adamantylamides of 1,3-diphenylpyrazole-4-carboxylic acids on the cytochrome P-450 system of the liver. Farmakol Toksikol 1991; 54: 39-41.
27. KLINGER W, MÜLLER D: The influence of age on the protein concentration in serum, liver and kidney of rats determined by various methods. Z Versuchstierk 1974; 16: 146-153.
28. KLINGER W, MÜLLER D: Ethylmorphine N-demethylation by liver homogenate of newborn and adult rats; enzyme kinetics and age course of Vmax and Km. Acta biol med germ 1977; 36: 1149-1159.
29. KORNHUBER J, QUACK G, DANYSZ W, et al.: Therapeutic brain concentrations of the NMDA receptor antagonist amantadine. Neuropharmacol 1995; 34: 713-721.
30. LEWIS DFV: Cytochromes P450: Structure, function and mechanism. Taylor & Francis, London 1996.
31. LOCH JM, POTTER J, BACHMANN KA: The influence of anesthetic agents on rat hepatic cytochrome P450 in vivo. Pharmacol 1995; 50: 146-153.
32. LUPP A, KERST S, KARGE E, et al.: Investigation on possible antioxidative properties of the NMDA-receptor antagonists ketamine, memantine, and amantadine in comparison to nicanartine in vitro. Exp Toxic Pathol 1998; 50: 501-506.
33. MEHTA TR, DAWSON R Jr: Taurine is a weak scavenger of peroxynitrite and does not attenuate sodium nitroprusside toxicity to cells in culture. Amino Acids 2001; 20: 419-433.
34. MÜLLER-PEDDINGHAUS R, WURL M: The amplified chemiluminescence test to characterize antirheumatic drugs as oxygen radical scavengers. Biochem Pharmacol 1987; 36:1125-1132.
35. MURAKAMI S, KONDO Y, TOMISAWA K, et al.: Prevention of atherosclerotic lesion development in mice by taurine. Drugs Exp Clin Res 1999; 25: 227-234.
36. NAKAMURA T, OGASAWARA M, KOYAMA T, et al.: The protective effect of taurine on the biomembrane against damage produced by oxygen radicals. Biol Pharm Bull 1993; 16: 970-972.
37. NASH T: The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochem J 1953, 55: 416-421.
38. NIESSEN F, ISSELHARD W, MINOR T: No beneficial effects of taurine application on oxygen free radical production after hemorrhagic shock in rats. Adv Exp Med Biol 1998; 442: 193-200.
39. OZ E, SIVRIKOZ MC, HALIT V, et al.: The role of taurine added to pulmonary reperfusion solutions in isolated guinea pig lungs. Amino Acids 2002; 22: 391-403.
40. PARSONS CG, QUACK G, BRESINK I, et al.: Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 1995; 34: 1239-1258.
41. POHL RJ, FOUTS JR: A rapid method for assaying the metabolism of 7-ethoxyresorufin by microsomal subcellular fractions. Anal Biochem 1980; 107: 150-155.
42. PRASAD KN, COLE WC, HOVLAND AR, et al.: Multiple antioxidants in the prevention and treatment of neurodegenerative disease: analysis of biologic rationale. Curr Opin Neurol 1999; 12: 761-770.
43. ROSLER M, RETZ W, THOME J, et al.: Free radicals in Alzheimer's dementia: currently available therapeutic strategies. J Neural Transm Suppl 1998; 54: 211-219.
44. SCHENKMAN JB, REMMER H, ESTABROOK RW: Spectral studies of drug interaction with hepatic microsomal cytochrome. Mol Pharmacol 1967; 3: 113-123.
45. SHI X, FLYNN DC, PORTER DW, et al.: Efficacy of taurine based compounds as hydroxyl radical scavengers in silica induced peroxidation. Ann Clin Lab Sci 1997; 27: 365-374.
46. SILMAN N, ARTMAN M, ENGELBERG H: Effect of magnesium and spermine on the aggregation of bacterial and mammalian ribosomes. Biochem Biophys Acta 1965; 103: 231-240.
47. SIMONIAN NA, COYLE JT: Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 1996; 36: 83-106.
48. TABNER BJ, TURNBULL S, EL AGNAF OM, et al.: Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic Biol Med 2002; 32: 1076-1083.
49. YANAGIHARA Y, KARIYA S, OHTANI M, et al.: Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2001; 29: 887-890.